Last edition
News about "Eylea biosimilar "
Biocon Announces US Commercial Launch of Yesafili, a Biosimilar to Regeneron's Eylea 2 mg
Biocon has launched Yesafili, an interchangeable biosimilar to Eylea 2 mg in the US, expanding access to treatment for Age-related Macular Degeneration (AMD) and other retinal diseases.
Eylea Biosimilar | 03/08/2026 | By News Bureau
Teva Pharma Launches AHZANTIVE Biosimilar to Eylea in Europe
Teva has launched AHZANTIVE (aflibercept), an EMA-approved biosimilar to Eylea, across Europe. Demonstrating comparable efficacy, safety, and immunogenicity to the reference product, the launch expands Teva’s biosimilars and ophthalmology portfolio while supporting its long-term Pivot to Growth strategy.
Eylea Biosimilar | 06/06/2026 | By News Bureau | 132
Alvotech Reaches Global Settlement on Eylea Biosimilar
The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.
Eylea Biosimilar | 30/01/2026 | By News Bureau | 289
European Commission approves EYLUXVI (ALT-L9) by Alteogen
EYLUXVI is the second biosimilar approved by the European Commission for Alteogen, following the launch of the Herceptin biosimilar in China through its partner Qilu Pharmaceutical.
Eylea Biosimilar | 18/09/2025 | By Dineshwori | 185
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy